Andrew I Spitzer, Michael A Mont, Jennifer H Lin, Vinod Dasa, Adam Rivadeneyra, David Rogenmoser, Andrew L Concoff, Mitchell K Ng, Mary DiGiorgi, Stan Dysart, Joshua Urban, William M Mihalko
{"title":"Treatment Journey for Nonoperative Symptomatic Knee Osteoarthritis: Data from a New Real-World Registry.","authors":"Andrew I Spitzer, Michael A Mont, Jennifer H Lin, Vinod Dasa, Adam Rivadeneyra, David Rogenmoser, Andrew L Concoff, Mitchell K Ng, Mary DiGiorgi, Stan Dysart, Joshua Urban, William M Mihalko","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There is a wide range of nonoperative options to manage symptomatic knee osteoarthritis (OA). This paper aimed to 1) define the treatment sequence for patients undergoing up to four subsequent rounds (i.e., cryoneurolysis) of superficial (Cryo-Superficial) and/or deep genicular nerves (Cryo-Deep/Both), intra-articular corticosteroid injections (IA-CS), triamcinolone extended-release (IA-TA-ER), hyaluronic acid (IA-HA), or non-steroidal anti-inflammatory drugs (IA-NSAIDs); 2) compare usage of extended-release versus standard corticosteroid injections; and 3) quantify distribution of repeated treatments.</p><p><strong>Materials and methods: </strong>We identified 502 patients with symptomatic knee OA and received nonoperative intervention within the Innovations in Genicular Outcomes (IGOR) registry from 2021 to 2024. Treatment journey during follow up was presented aggregating baseline patient demographics, along with sequence of nonoperative treatments per patient, duration, and frequency of repeated use. Repeated use of Round 1 treatment for subsequent treatment rounds was estimated with descriptive statistics.</p><p><strong>Results: </strong>Fifty-three percent of patients received only the original Round 1 treatment option, either single/repeated dose and did not receive any alternative treatment. Seventy-three percent of patients treated with intra-articular extended-release triamcinolone (IA-TAER) repeated the treatment at least once, whereas 60% of those treated with other treatments did so. No adverse events were reported in patients during repeated treatments.</p><p><strong>Conclusion: </strong>Patients who received IA-TAER were more likely to repeat the same injection, with 73% repeating at least once and no adverse events were attributed to repeated injections. Approximately half of the patients have switched from the initial treatment offered during follow up, with the use of IA-TAER associated with higher rates of repeated treatment. Significance and Innovation 1. Our study used a newly developed real-world registry IGOR to characterize treatment progression for patients with symptomatic knee OA undergoing up to five rounds of nonoperative treatment. 2. Non-surgical interventions included cryoneurolysis, intra-articular injections of NSAIDs, hyaluronic acid injections, corticosteroid, or extended release steroid (triamcinolone) injections. 3. We found 73% of patients treated with intra-articular extended-release steroid injections repeated treatment at least once, relative to 60% by other treatments. 4. We found approximately half of patients switched from initial treatment offered during follow up, with the use of IA-TAER associated with higher rates of repeated treatment.</p>","PeriodicalId":22194,"journal":{"name":"Surgical technology international","volume":"45 ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical technology international","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
摘要
导言:治疗无症状膝关节骨性关节炎(OA)的非手术疗法种类繁多。本文旨在:1)确定接受最多四轮后续治疗(即冷冻神经溶解)的患者的治疗顺序、冷冻神经溶解术)、关节内皮质类固醇注射(IA-CS)、曲安奈德缓释剂(IA-TA-ER)、透明质酸(IA-HA)或非类固醇抗炎药(IA-NSAIDs);2)比较缓释皮质类固醇注射与标准皮质类固醇注射的使用情况;以及 3)量化重复治疗的分布情况。材料和方法:我们确定了 502 名有症状的膝关节 OA 患者,他们在 2021 年至 2024 年期间接受了基因结果创新(IGOR)登记处的非手术治疗。在随访过程中,我们汇总了患者的基线人口统计数据、每位患者接受非手术治疗的顺序、持续时间以及重复使用的频率。通过描述性统计估计了第一轮治疗在后续治疗中的重复使用情况:结果:53%的患者只接受了最初的第一轮治疗方案,包括单剂/重复剂量,没有接受任何替代治疗。在接受关节腔内缓释曲安奈德(IA-TAER)治疗的患者中,73%的患者至少重复了一次治疗,而在接受其他治疗的患者中,60%的患者重复了一次治疗。结论:接受IA-TAER治疗的患者在重复治疗期间未出现不良反应:结论:接受IA-TAER治疗的患者更有可能重复注射同一种药物,73%的患者至少重复注射一次,重复注射未导致不良反应。在随访期间,约有一半的患者从最初提供的治疗方法中进行了转换,使用 IA-TAER 的患者重复治疗的比例较高。意义与创新 1.我们的研究使用了新开发的真实世界登记系统 IGOR 来描述接受多达五轮非手术治疗的无症状膝关节 OA 患者的治疗进展情况。2.2. 非手术治疗包括冷冻神经溶解术、非甾体抗炎药物关节内注射、透明质酸注射、皮质类固醇或缓释类固醇(曲安奈德)注射。3.3. 我们发现,在接受关节内缓释类固醇注射治疗的患者中,有 73% 的患者至少重复治疗一次,而接受其他治疗的患者只有 60%。4.4. 我们发现约有一半的患者在随访期间更换了最初提供的治疗方法,而使用关节腔内缓释类固醇注射与较高的重复治疗率有关。
Treatment Journey for Nonoperative Symptomatic Knee Osteoarthritis: Data from a New Real-World Registry.
Introduction: There is a wide range of nonoperative options to manage symptomatic knee osteoarthritis (OA). This paper aimed to 1) define the treatment sequence for patients undergoing up to four subsequent rounds (i.e., cryoneurolysis) of superficial (Cryo-Superficial) and/or deep genicular nerves (Cryo-Deep/Both), intra-articular corticosteroid injections (IA-CS), triamcinolone extended-release (IA-TA-ER), hyaluronic acid (IA-HA), or non-steroidal anti-inflammatory drugs (IA-NSAIDs); 2) compare usage of extended-release versus standard corticosteroid injections; and 3) quantify distribution of repeated treatments.
Materials and methods: We identified 502 patients with symptomatic knee OA and received nonoperative intervention within the Innovations in Genicular Outcomes (IGOR) registry from 2021 to 2024. Treatment journey during follow up was presented aggregating baseline patient demographics, along with sequence of nonoperative treatments per patient, duration, and frequency of repeated use. Repeated use of Round 1 treatment for subsequent treatment rounds was estimated with descriptive statistics.
Results: Fifty-three percent of patients received only the original Round 1 treatment option, either single/repeated dose and did not receive any alternative treatment. Seventy-three percent of patients treated with intra-articular extended-release triamcinolone (IA-TAER) repeated the treatment at least once, whereas 60% of those treated with other treatments did so. No adverse events were reported in patients during repeated treatments.
Conclusion: Patients who received IA-TAER were more likely to repeat the same injection, with 73% repeating at least once and no adverse events were attributed to repeated injections. Approximately half of the patients have switched from the initial treatment offered during follow up, with the use of IA-TAER associated with higher rates of repeated treatment. Significance and Innovation 1. Our study used a newly developed real-world registry IGOR to characterize treatment progression for patients with symptomatic knee OA undergoing up to five rounds of nonoperative treatment. 2. Non-surgical interventions included cryoneurolysis, intra-articular injections of NSAIDs, hyaluronic acid injections, corticosteroid, or extended release steroid (triamcinolone) injections. 3. We found 73% of patients treated with intra-articular extended-release steroid injections repeated treatment at least once, relative to 60% by other treatments. 4. We found approximately half of patients switched from initial treatment offered during follow up, with the use of IA-TAER associated with higher rates of repeated treatment.